BiotechTube
Aurita Bioscience

Aurita Bioscience

Pre-clinical
Gainesville, United StatesFounded 2019auritabio.com

Aurita Bioscience is a private biotechnology company developing a disruptive 3D cell culture ecosystem designed to overcome the limitations of traditional 2D and hydrogel-based 3D models. Its core technologies—LLS® microgels and Darcy™ perfusion plates—create a tunable, physiologically relevant microenvironment that supports complex cellular interactions, prolonged viability, and high-fidelity in situ imaging. The company is actively engaged in collaborative research projects in oncology, infectious disease (including SARS-CoV-2), and immunotherapy (CAR-T), positioning itself as a critical enabler for more predictive drug discovery and development.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $4.2M

AI Company Overview

Aurita Bioscience is a private biotechnology company developing a disruptive 3D cell culture ecosystem designed to overcome the limitations of traditional 2D and hydrogel-based 3D models. Its core technologies—LLS® microgels and Darcy™ perfusion plates—create a tunable, physiologically relevant microenvironment that supports complex cellular interactions, prolonged viability, and high-fidelity in situ imaging. The company is actively engaged in collaborative research projects in oncology, infectious disease (including SARS-CoV-2), and immunotherapy (CAR-T), positioning itself as a critical enabler for more predictive drug discovery and development.

OncologyInfectious DiseaseImmunology

Technology Platform

Aurita's core platform consists of patented Liquid-Like Solids (LLS®) microgels, a tunable 3D culture medium, integrated with Darcy™ perfusion plates that emulate capillary bed fluid dynamics, enabling highly biomimetic in vitro models for drug discovery.

Funding History

1
Total raised:$4.2M
Seed$4.2MMay 15, 2022

Opportunities

Significant growth opportunities exist in the booming immunotherapy R&D sector, where Aurita's iVITA™ assays can become a standard tool.
The push towards personalized medicine and functional precision oncology also presents a major market for its patient-derived explant models.
Furthermore, the need for human-relevant models for emerging infectious diseases provides a recurring application area.

Risk Factors

Key risks include slow adoption by researchers accustomed to traditional methods, potential competition from larger, well-funded life science tools companies, and the ongoing need for capital to scale operations without disclosed major funding rounds.
The company's success is heavily dependent on securing high-profile validation partnerships.

Competitive Landscape

Aurita competes with traditional 3D matrix providers (Corning/Matrigel) and organ-on-a-chip companies (Emulate, Mimetas). Its primary differentiation lies in the unique physical properties of its LLS® microgel medium (liquid handling, solid support) and its integrated, plate-based perfusion system, which aims to offer superior biomimicry with greater accessibility than complex microfluidic chips.